{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:14Z","timestamp":1791920894646,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clml.2020.11.025","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:42:50Z","timestamp":1607042570000},"page":"e255-e263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5036-9370","authenticated-orcid":false,"given":"Nafie F.","family":"Makady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ramzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Ghaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raafat R.","family":"Abdel-Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-3605","authenticated-orcid":false,"given":"Kyrillus S.","family":"Shohdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.11.025_bib1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.025_bib2","series-title":"WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues","first-page":"256","article-title":"Plasmablastic lymphoma","author":"Stein","year":"2008"},{"key":"10.1016\/j.clml.2020.11.025_bib3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdw684","article-title":"Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group","volume":"28","author":"Tchernonog","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.11.025_bib4","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1080\/10428194.2017.1416365","article-title":"Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis","volume":"59","author":"Dittus","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.11.025_bib5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.025_bib6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00259-018-4020-5","article-title":"Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in plasmablastic lymphoma","volume":"45","author":"Al Tabaa","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2020.11.025_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clml.2015.12.008","article-title":"Doxorubicin-based chemotherapy and radiation therapy produces favorable outcomes in limited-stage plasmablastic lymphoma: a single-institution review","volume":"16","author":"Pinnix","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.11.025_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-015-0163-z","article-title":"Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients","volume":"8","author":"Loghavi","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.clml.2020.11.025_bib9","doi-asserted-by":"crossref","first-page":"8583","DOI":"10.1200\/jco.2014.32.15_suppl.8583","article-title":"Treatment of HIV-associated plasmablastic lymphoma: a single-center experience with 25 patients","volume":"32","author":"Ibrahim","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.025_bib10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases","volume":"83","author":"Castillo","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.11.025_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","article-title":"Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma","volume":"15","author":"Castillo","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.11.025_bib12","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.11.025_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/sajc.sajc_186_16","article-title":"Plasmablastic lymphoma in immunocompetent and in immunocompromised patients: experience at a regional cancer centre in India","volume":"6","author":"Rudresha","year":"2017","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.clml.2020.11.025_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/hiv.12624","article-title":"Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study","author":"Foc\u00e0","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.clml.2020.11.025_bib15","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3892\/or.2015.3808","article-title":"Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clml.2020.11.025_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2017.09.020","article-title":"Bortezomib in plasmablastic lymphoma: a glimpse of hope for a hard-to-treat disease","volume":"62","author":"Guerrero-Garcia","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.11.025_bib17","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/modpathol.2010.72","article-title":"Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features","volume":"23","author":"Taddesse-Heath","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2020.11.025_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13027-018-0195-4","article-title":"Plasmablastic lymphoma in Malawi","volume":"13","author":"Zuze","year":"2018","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.clml.2020.11.025_bib19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/jop.12753","article-title":"Clinicopathological analysis of oral plasmablastic lymphoma: a systematic review","volume":"47","author":"Rodrigues-Fernandes","year":"2018","journal-title":"J\u00a0Oral Pathol Med"},{"key":"10.1016\/j.clml.2020.11.025_bib20","article-title":"A\u00a0robust gene expression signature to predict proteasome inhibitor benefit in multiple myeloma","volume":"2019","author":"Ubels","year":"2019","journal-title":"medRxiv"},{"key":"10.1016\/j.clml.2020.11.025_bib21","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2018-05-849893","article-title":"RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib\/lenalidomide decision signature","volume":"132","author":"Chapman","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.025_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-015-0374-0","article-title":"Aggressive B cell lymphoma: optimal therapy for MYC-positive, double-hit, and triple-hit DLBCL","volume":"16","author":"Dunleavy","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clml.2020.11.025_bib23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1365-2559.2012.04339.x","article-title":"Plasmablastic lymphoma of the elderly: a clinicopathological comparison with age-related Epstein-Barr virus-associated B cell lymphoproliferative disorder","volume":"61","author":"Liu","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.clml.2020.11.025_bib24","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","article-title":"IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas","volume":"34","author":"Valera","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2020.11.025_bib25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41375-018-0320-9","article-title":"Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma","volume":"33","author":"Dodero","year":"2019","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.11.025_bib26","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1182\/blood-2019-124350","article-title":"Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) treatment in dual expressor diffuse large B-cell and double\/triple hit lymphomas: TP53 mutations influence on clinical outcome","volume":"134","author":"Dodero","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.025_bib27","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1182\/blood.V128.22.5410.5410","article-title":"Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubucin and rituximab (da-EPOCH-R) vs rituxan, cyclophosphamide, doxorubucin, vincristine and prednisone (R-CHOP) as first line treatment for diffuse large B-cell lymphoma (DLBCL)","volume":"128","author":"Padhi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.025_bib28","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.025_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.13300","article-title":"Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.025_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00277-016-2601-6","article-title":"Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma","volume":"95","author":"Fedele","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.11.025_bib31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.11.025_bib32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.025_bib33","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.025_bib34","first-page":"443","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphoma","volume":"30","author":"Murthy","year":"2017","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.clml.2020.11.025_bib35","doi-asserted-by":"crossref","first-page":"12168","DOI":"10.1038\/srep12168","article-title":"Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age","volume":"5","author":"Lu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2020.11.025_bib36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/TP.0b013e318242162d","article-title":"Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective german posttransplant lymphoproliferative disorder registry","volume":"93","author":"Zimmermann","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2020.11.025_bib37","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/QAD.0b013e32835e069d","article-title":"Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study","volume":"27","author":"Schommers","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.clml.2020.11.025_bib38","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3109\/10428194.2010.516040","article-title":"Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma","volume":"51","author":"Castillo","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.11.025_bib39","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.2019003959","article-title":"Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)","volume":"136","author":"Ramos","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020306674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020306674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:36:19Z","timestamp":1730529379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020306674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2152265020306674"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.11.025","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}